Pelthos Therapeutics Inc.
Price Action
Technical Summary
CONSOLIDATINGPelthos Therapeutics Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 55), indicating performance broadly in line with the market. Earnings contraction of 8% provides fundamental context to the price action. Investors should exercise caution due to high volatility (150% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $22.87 | +15.26% | ABOVE |
| 50 SMA | $24.61 | +7.13% | ABOVE |
| 100 SMA | $27.04 | -2.50% | BELOW |
| 150 SMA | $26.68 | -1.21% | BELOW |
| 200 SMA | $— | — |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is PTHS in an uptrend right now?
PTHS has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is PTHS overbought or oversold?
PTHS's RSI (14) is 52. The stock is in neutral territory, neither overbought nor oversold.
Is PTHS outperforming the market?
PTHS has a Relative Strength (RS) Rating of 55 out of 99. PTHS is performing about average compared to the market.
Where is PTHS in its 52-week range?
PTHS is trading at $26.36, which is 49% of its 52-week high ($54.29) and 35% above its 52-week low ($11.20).
How volatile is PTHS?
PTHS has a Beta of 0.76 and 52-week volatility of 150%. It's less volatile than the S&P 500 - generally more stable.